drugset / Trial / NCT06613841

Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma

NCT06613841

Phase 0 Recruiting 15 enrolled Abramson Cancer Center at Penn Medicine
NaSingle-groupOpen-labelDiagnostic

Summary

* To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer \[18F\]Fluciclovine and 18F-FDG PET. * To compare uptake measures of 18F-Fluciclovine and 18F-FDG and MRI quantification of glutamate and lactate levels to tumor tissue laboratory assays (RNA seq and proteomics) of glutamine/glutamate, glucose, and lactate metabolism. * To perform metabolic phenotyping of treatment naïve and recurrent GBM by advanced MRI methods at 7 Tesla

Timeline

Start
2025-05-01
Primary completion
2026-10-01
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-fluciclovine Diagnostic / imaging agent 74 mbq Other

Indications